Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy

Hennessey, Alex; Buller, Dylan; Sama, Shashank; Girard, Eric; Clément, Jessica; Ristau, Benjamin T.

doi:10.1016/j.eucr.2019.101084

Cited by 6 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASCP is histologically defined by the presence of both glandular and squamous components [ 4 , 5 ]. Two-thirds of ASCP patients reportedly had had prior ADT and/or radiation therapy for acinar adenocarcinoma of the prostate [ 4 – 6 , 8 – 10 , 13 , 16 , 17 , 22 ], whereas the remaining one-third of patients were considered de novo cases [ 7 , 11 , 12 , 14 , 15 , 18 – 21 , 23 – 25 ]. The present case developed after primary ADT for Gleason grade group 5 PC.…”

Section: Discussionmentioning

confidence: 99%

“…ASCP was first described by Thompson in 1942 [ 3 ], and is defined by the presence of both glandular and squamous components [ 4 , 5 ]. Among published ASCP cases [ 4 – 25 ], two-thirds of patients had had prior androgen deprivation therapy (ADT) and/or radiation therapy for acinar adenocarcinoma of the prostate [ 4 – 6 , 8 – 10 , 13 , 16 , 17 , 22 ], whereas the remaining one-third of patients were considered de novo cases [ 7 , 11 , 12 , 14 , 15 , 18 – 21 , 23 – 25 ]. Owing to its extreme rarity, little is known about genomic characteristics of ASCP [ 13 , 14 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report

et al. 2021

View full text Add to dashboard Cite

Background Adenosquamous carcinoma of the prostate (ASCP) is an extremely rare and aggressive prostate cancer variant, whose genomic characteristics have not been elucidated. Although liquid biopsy of circulating tumor cells (CTCs) is an emerging topic in oncology, no study has assessed CTCs in patients with ASCP. Case presentation. A 76-year-old man presented with discomfort in his urethra. His prostate-specific antigen (PSA) level was 13.37 ng/mL. A computed tomography (CT) scan indicated a prostate mass with multiple lymph node and lung metastases. The patient underwent transurethral resection of the prostate and prostatic needle biopsy; both specimens demonstrated Gleason grade group 5 acinar adenocarcinoma of the prostate. Bone scintigraphy indicated bone metastasis in the ischium. Combined androgen blockade was implemented, and his serum PSA level rapidly decreased to 0.01 ng/mL. However, a CT scan 6 months after the initial diagnosis revealed worsening of the disease. The patient therefore underwent repeated prostatic needle biopsy; its specimen demonstrated prostatic adenocarcinoma together with squamous carcinoma components. As immunohistochemical analyses showed the tumor cells to be negative for CD56, chromogranin A, synaptophysin, and PSA, the definitive diagnosis was ASCP. Although the patient underwent chemotherapy (docetaxel and cabazitaxel), he died of the disease 3 months after the diagnosis of ASCP, or 13 months after the initial diagnosis of prostatic adenocarcinoma. His PSA values remained ≤ 0.2 ng/mL. CTCs from the patient’s blood (collected before starting docetaxel) were analyzed and genomically assessed. It showed 5 cytokeratin (CK)+ CTCs, 14 CK− CTCs, and 8 CTC clusters, per 10 mL. Next-generation sequencing identified a total of 14 mutations in 8 oncogenes or tumor suppressor genes: PIK3CB, APC, CDKN2A, PTEN, BRCA2, RB1, TP53, and CDK12. Of 14 mutations, 9 (64%) were detected on CK− CTCs and 5 (36%) were detected on CK+ CTCs. Conclusions This is the first report of CTC analysis and genomic assessment in ASCP. Although the prognosis of ASCP is dismal due to lack of effective treatment, genomic analysis of CTCs might lead to effective treatment options and improved survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These carcinomas are highly resistant to radiation and chemotherapy. 3,6,7 The squamous component is quiescent and hence, therapy targeting rapidly proliferating tumour cells fail in this subtype. The best documented choice of treatment is aggressive surgery; however, the prognosis is generally dismal.…”

Section: Discussionmentioning

confidence: 99%

Adenosquamous carcinoma of prostate: An entity out of the ordinary

Sreeram,

Agarwal,

Kini

2023

IJPO

View full text Add to dashboard Cite

Adenosquamous carcinoma (ASC) of the prostate is an extremely rare, aggressive histological subtype of prostate cancer. We report one such case here of a 73-year-old man with prostatic malignancy with a combination of squamous and glandular components. Immunohistochemistry with p40, AMACR and HMWCK corroborated the diagnosis of ASC. The squamous component being refractory, is better amenable to aggressive surgery, highlighting the importance of recognising this entity. Bony metastasis was not seen in this patient. Serum PSA was near normal.

show abstract

“…Risk factors for the development of prostatic adenosquamous carcinoma can include prior radiation and/or hormonal therapy [6], none of which our patient had received. There have been several documented cases of pASC in the absence of hormonal or radiotherapy, and some authors have suggested that this may reflect pluripotent cells capable of multidirectional differentiation [7].…”

Section: Discussionmentioning

confidence: 99%

“…Due to the small number of cases present in the literature, optimal treatment for this malignancy is controversial. Hennessey et al recently reported a case of de novo pASC treated with a multimodal approach including surgery, androgen-deprivation therapy (ADT), docetaxel chemotherapy, and radiation with a good radiologic and clinical improvement 20 months post treatment [7].…”

Section: Discussionmentioning

confidence: 99%

Primary Adenosquamous Carcinoma of the Prostate with Rectal Invasion

Azzi

Bossé

Cagiannos

et al. 2022

Case Reports in Urology

View full text Add to dashboard Cite

Prostate adenosquamous carcinoma (pASC) is a rare form of prostate cancer accounting for <1% of all cases. It is generally considered an aggressive variant often presenting with significant symptom burden and/or metastatic disease. Given its rarity, optimal management of this cancer is unknown. We present a case of a patient with pASC treated with radiotherapy and chemotherapy with excellent symptomatic improvement and local control.

show abstract

Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy

Cited by 6 publications

References 5 publications

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report

Adenosquamous carcinoma of prostate: An entity out of the ordinary

Primary Adenosquamous Carcinoma of the Prostate with Rectal Invasion

Contact Info

Product

Resources

About